| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| A1032-100 | Anti-human CCR8, H9S1 | 100µg | $185 | Order |
| A1032-200 | Anti-human CCR8, H9S1 | 200µg | $325 | Order |
| Catalog Number | A1032 |
|---|---|
| Product Name | Anti-human CCR8 |
| Source | Purified mouse antibody from hybridoma |
| Clone | H9S1 |
| Species Reactivity | Human CCR8, does not cross-react to cyno CCR8 |
| Isotype | Mouse IgG1 |
| Purity | >95% |
| Formulation | 1xPBS, pH6.9. Sterile |
| Stability & Storage | 1 month at 4oC; 12 months at <-20oC; Avoid repeated freeze-thaw |
| Protein Aggregation | Not obvious on SDS-PAGE |
| Application | Flow cytometry, ELISA, cell-based assay |
| Product Datasheet: | Download PDF |
Detection of human CCR8 expression on human CCR8-CHO-K1 stable cell line (Cat. #C3032) using the anti-human CCR8, clone H9S1 (Cat. #A1032).
CCR8, also known as CY6, TER1, CCR-8, CKRL1, CDw198, CMKBR8, GPRCY6, CMKBRL2, CC-CKR-8, is a C-C motif chemokine receptor of the G protein coupled receptor (GPCR) family and is expressed on the cell surface of regulatory T cells (Tregs). Activation of CCR8 by binding of C-C motif chemokine ligands CCL1, CCL8, CCL16 and CCL18 can lead to activating the functionality of Tregs in immune response suppression. CCR8 expression is upregulated and highly expressed in many cancers such as bladder, breast, and colorectal cancer increasing migration and invasion activity and antiapoptosis in Tregs. This activity shows an association between CCR8 expression and cancer progression making CCR8 a potential target molecule for cancer immunotherapy.
Saito M, Suzuki H, Tanaka T, Asano T, Kaneko MK, Kato Y. Development of an Anti-Mouse CCR8 Monoclonal Antibody (C8Mab-1) for Flow Cytometry and Immunocytochemistry. Monoclon Antib Immunodiagn Immunother. 2022.